ProShare Advisors LLC Buys 6,119 Shares of Zoetis Inc. $ZTS

ProShare Advisors LLC lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.6% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 115,215 shares of the company’s stock after acquiring an additional 6,119 shares during the period. ProShare Advisors LLC’s holdings in Zoetis were worth $8,045,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Vise Technologies Inc. grew its holdings in Zoetis by 52.9% during the third quarter. Vise Technologies Inc. now owns 14,886 shares of the company’s stock valued at $1,039,000 after purchasing an additional 5,151 shares during the last quarter. Cidel Asset Management Inc. lifted its stake in shares of Zoetis by 17.5% in the third quarter. Cidel Asset Management Inc. now owns 4,003 shares of the company’s stock worth $280,000 after buying an additional 595 shares during the last quarter. State of Wyoming lifted its stake in shares of Zoetis by 120.9% in the third quarter. State of Wyoming now owns 4,540 shares of the company’s stock worth $317,000 after buying an additional 2,485 shares during the last quarter. International Assets Investment Management LLC lifted its stake in shares of Zoetis by 204.8% in the third quarter. International Assets Investment Management LLC now owns 20,000 shares of the company’s stock worth $1,397,000 after buying an additional 13,439 shares during the last quarter. Finally, Soltis Investment Advisors LLC boosted its holdings in shares of Zoetis by 58.9% during the 3rd quarter. Soltis Investment Advisors LLC now owns 129,952 shares of the company’s stock worth $9,075,000 after buying an additional 48,180 shares during the period. Institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. lowered their target price on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Morgan Stanley cut their target price on shares of Zoetis from $85.00 to $82.00 and set an “overweight” rating for the company in a research report on Thursday, October 29th. Piper Sandler decreased their price target on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, August 10th. UBS Group boosted their price objective on Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 27th. Finally, Zacks Research raised Zoetis from a “strong sell” rating to a “hold” rating in a research report on Monday, October 26th. Six investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $93.79.

Zoetis Stock Performance

ZTS opened at $88.60 on Thursday. The stock’s 50 day simple moving average is $75.50 and its 200-day simple moving average is $93.03. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The stock has a market cap of $36.61 billion, a PE ratio of 14.60, a P/E/G ratio of 1.23 and a beta of 0.67. Zoetis Inc. has a 1 year low of $68.77 and a 1 year high of $132.49.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.76 earnings per share. Sell-side analysts forecast that Zoetis Inc. will post 6.15 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.